Metformin
- Generic Name
- Metformin
- Brand Names
- Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo
- Drug Type
- Small Molecule
- Chemical Formula
- C4H11N5
- CAS Number
- 657-24-9
- Unique Ingredient Identifier
- 9100L32L2N
- Background
Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.
Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels. Another well-known benefit of this drug is modest weight loss, making it an effective choice for obese patients type II diabetes.
Metformin was first approved in Canada in 1972, and received subsequent FDA approval in the US in 1995.
- Indication
Metformin immediate-release formulations
Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.
Metformin extended-release tablet (XR)
The extended-release formulation of metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Safety in children has not been determined to this date.
Metformin combination products
Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors (sitagliptin, linagliptin, alogliptin, or saxagliptin), in combination with SGLT2 inhibitors (canagliflozin, empagliflozin, ertugliflozin, or dapagliflozin), or in combination with pioglitazone.
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
- Associated Therapies
- -
Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2021-05-11
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 954
- Registration Number
- NCT03332771
- Locations
- 🇺🇸
Investigational Site Number 8407074, Bradenton, Florida, United States
🇺🇸Investigational Site Number 8407111, Dallas, Texas, United States
🇺🇸Investigational Site Number 8407078, Carmichael, California, United States
Comparison of Metformin and Insulin for Management of Gestational Diabetes Mellitus
- Conditions
- Gestational Diabetes Mellitus in Pregnancy
- Interventions
- Drug: InsulinDrug: Metformin
- First Posted Date
- 2017-10-25
- Last Posted Date
- 2017-10-27
- Lead Sponsor
- Services Institute of Medical Sciences, Pakistan
- Target Recruit Count
- 278
- Registration Number
- NCT03320694
- Locations
- 🇵🇰
Services Institute of Medical Sciences, Lahore, Punjab, Pakistan
A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma
- Conditions
- Advanced Melanoma
- Interventions
- First Posted Date
- 2017-10-17
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Yana Najjar
- Target Recruit Count
- 30
- Registration Number
- NCT03311308
- Locations
- 🇺🇸
Univ of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
An Assessment of Pharmacokinetic Gemigliptin and Metformin Interactions in Healthy Mexican Volunteers
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2017-10-16
- Last Posted Date
- 2017-10-16
- Lead Sponsor
- Stendhal Americas, S.A.
- Target Recruit Count
- 34
- Registration Number
- NCT03310749
- Locations
- 🇲🇽
Unidad de Farmacología Clínica de la Facultad de Medicina de la Universidad Nacional Autónoma de México, Nezahualcóyotl, Estado de México, Mexico
A Double-Blind, Placebo-Controlled Trial of Anti-Aging, Pro-Autophagy Effects of Metformin in Adults With Prediabetes
- First Posted Date
- 2017-10-13
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- University of New Mexico
- Target Recruit Count
- 25
- Registration Number
- NCT03309007
- Locations
- 🇺🇸
University of New Mexico Clincal & Translational Science Center, Albuquerque, New Mexico, United States
This Study Tests the Effect of Certain Medicines on the Transport of Other Medicines in the Body of Healthy Men
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2017-10-11
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 45
- Registration Number
- NCT03307252
- Locations
- 🇩🇪
CTC North GmbH & Co. KG, Hamburg, Hamburg, Germany
Metformin Treatment on Cognitive Impairment of Schizophrenia Co-morbid Metabolic Syndrome
- First Posted Date
- 2017-09-05
- Last Posted Date
- 2023-04-11
- Lead Sponsor
- Central South University
- Target Recruit Count
- 80
- Registration Number
- NCT03271866
- Locations
- 🇨🇳
The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
A Study to Assess the Effect of Plazomicin on the Pharmacokinetics of Metformin
- First Posted Date
- 2017-09-01
- Last Posted Date
- 2017-10-11
- Lead Sponsor
- Achaogen, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT03270553
- Locations
- 🇺🇸
Clinical Site, Lincoln, Nebraska, United States
Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2017-08-31
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1264
- Registration Number
- NCT03268005
- Locations
- 🇺🇦
Novo Nordisk Investigational Site, Vinnytsia, Ukraine
An Efficacy Study of Canagliflozin or Sitagliptin to Determine Glucose Variability in Mexican Participants With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2017-08-30
- Last Posted Date
- 2019-11-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 64
- Registration Number
- NCT03267576
- Locations
- 🇲🇽
Investigación Clínica Especializada, Guadalajara, Mexico
🇲🇽Consultorio Privado en Unidad de Patología Clínica, Guadalajara, Mexico
🇲🇽Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.